The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases

J Alijotas-Reig, R Ferrer-Oliveras, A Ruffatti… - Autoimmunity …, 2015 - Elsevier
Aim To analyse the clinical features, laboratory data, foetal–maternal outcomes, and follow-
up in a cohort of 247 women with obstetric antiphospholipid syndrome (OAPS). Methods The …

[HTML][HTML] Myositis autoantibodies and clinical phenotypes

A Ghirardello, E Borella, M Beggio, F Franceschini… - Autoimmunity …, 2014 - Springer
Autoantibodies are powerful diagnostic tools in idiopathic inflammatory myopathies,
especially for confirming the diagnosis and contributing to the definition of disease subsets …

Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study

L Musset, Y Allenbach, O Benveniste, O Boyer… - Autoimmunity …, 2016 - Elsevier
In an effort to find naturally occurring substances that reduce cholesterol by inhibiting 3-
hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), statins were first discovered by …

[HTML][HTML] COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study

M Fredi, I Cavazzana, L Moschetti… - The Lancet …, 2020 - thelancet.com
Background The highest number of COVID-19 cases in Italy have been reported in
Lombardy, a region in northern Italy. We aimed to analyse the course of severe acute …

[HTML][HTML] Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis

A Ceribelli, M Fredi, M Taraborelli, I Cavazzana… - Arthritis research & …, 2012 - Springer
Introduction Autoantibodies in patients with polymyositis/dermatomyositis (PM/DM) are
associated with unique subsets, clinical course and outcome. Anti-MJ antibodies, which …

Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

MF Ugarte-Gil, GS Alarcón, Z Izadi… - Annals of the …, 2022 - ard.bmj.com
Aim To determine characteristics associated with more severe outcomes in a global registry
of people with systemic lupus erythematosus (SLE) and COVID-19. Methods People with …

[HTML][HTML] Systemic sclerosis-specific antibodies: novel and classical biomarkers

I Cavazzana, T Vojinovic, P Airo', M Fredi… - Clinical Reviews in …, 2023 - Springer
Disease-specific autoantibodies are considered the most important biomarkers for systemic
sclerosis (SSc), due to their ability to stratify patients with different severity and prognosis …

Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus

L Iaccarino, S Bettio, R Reggia, M Zen… - Arthritis Care & …, 2017 - Wiley Online Library
Objective To investigate effectiveness and safety of belimumab in patients with active
systemic lupus erythematosus (SLE) in a clinical practice setting. Methods Sixty‐seven …

Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera

I Cavazzana, M Fredi, A Ceribelli, C Mordenti… - Journal of …, 2016 - Elsevier
Objective To analyze the performance of a line blot assay for the identification of
autoantibodies in sera of patients affected by myositis, compared with immunoprecipitation …

Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real‐life setting

M Gatto, F Saccon, M Zen, F Regola… - Arthritis & …, 2020 - Wiley Online Library
Objective To investigate predictors of response, remission, low disease activity, damage,
and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were …